What is the future for cancer clinical trials? - Wikidata - awgldk - TriplyDB

What is the future for cancer clinical trials?

What is the future for cancer clinical trials?

http://www.wikidata.org/entity/Q48639219

about

What is the future for cancer clinical trials?

http://www.wikidata.org/entity/Q48639219

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

What is the future for cancer clinical trials?

@en

What is the future for cancer clinical trials?

@nl

type

label

What is the future for cancer clinical trials?

@en

What is the future for cancer clinical trials?

@nl

prefLabel

What is the future for cancer clinical trials?

@en

What is the future for cancer clinical trials?

@nl

P1433

Q48639219-192A8520-4F9E-40D8-8A44-FD89344D2002

P1476

Q48639219-3C7C30E0-1672-4D2D-909E-772306E81A6E

P2093

Q48639219-FDED1503-62B2-4287-8DCE-E49F0566B3B0

P2860

Q48639219-1F615E29-9953-438E-9AAB-FFD16E0C8B61

Q48639219-20DCC981-1060-40FE-96F3-90805E8DEF06

Q48639219-2A711D57-AB0F-490B-91D8-8F037AAF7BC1

Q48639219-3B998F1C-7F0E-4744-B7B1-63ABE9604E7A

Q48639219-3FCCFB57-4B1D-4BD4-B35D-5CAD7BBCC88E

Q48639219-42608E3B-9E26-4723-BC9D-B8098CB0C97A

Q48639219-435BDA37-3D63-4ABD-94C7-19979D83B752

Q48639219-43DC154F-D60D-4F93-90E6-945309037455

Q48639219-4683CAD0-5C1E-43A1-98C0-6C04D42733DB

Q48639219-472C8AB4-0838-40BC-946E-CC02F7F59F02

P304

Q48639219-77E6B65C-6CBE-4F94-8B1F-0512206D8E25

P31

Q48639219-3d9ea1e6-79e0-40b0-98f8-7ef53a8cb9b3

Q48639219-99F6A208-D208-4C76-8EF1-F38B35CB5016

P356

Q48639219-0298C847-1C24-4E16-9A1E-D5A279DAA612

P407

Q48639219-91F8C4DD-9683-4BB7-8EDA-3900C1732FEC

P433

Q48639219-488DC089-F78E-49FF-B539-006ED35CEBF6

P478

Q48639219-323DDAB8-87DA-4DE8-AF66-0035BE125D11

P577

Q48639219-4C004A4B-DE67-42E9-9268-AD8A0EE0BBB3

P698

Q48639219-DAC7813F-AB04-43D6-BC6E-99A6764AA4BE

P356

P1433

Future Oncology

P1476

What is the future for cancer clinical trials?

@en

P2093

Francesco Perrone

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

P304

5-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.183

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25572779

http://www.w3.org/2001/XMLSchema#string